CAJ | 학술논문

目的：建立人卵巢癌顺铂耐药细胞株 OVCAR-3/DDP,初步探讨其耐药机制。方法采用顺铂(DDP)浓度梯度递增诱导法,建立人卵巢癌 OVCAR-3细胞株的顺铂耐药细胞株 OVCAR-3/DDP；通过细胞计数和 MTT 法评估细胞增殖情况,流式细胞仪检测细胞周期情况,以评价 OVCAR-3/DDP 的生物学特性；采用 RT-PCR 法检测 Mfn2、EGFR 及 MMP2 mRNA 水平。结果成功建立了 OVCAR-3/DDP 顺铂耐药细胞株,其对 DDP 耐药指数是1.92；与亲本细胞株 OVCAR-3相比,OVCAR-3/DDP 生长速度减慢,倍增期是 OVCAR-3细胞的1.36倍(P <0.05)；流式细胞术检测结果显示细胞主要停滞于G2/M 期(P <0.05)；与 OVCAR-3细胞相比,OVCAR-3/DDP 细胞中 Mfn2、EGFR 及 MMP2 mRNA水平均明显升高(P <0.05)。结论建立的 OVCAR-3/DDP 细胞株对顺铂耐药性稳定；OVCAR-3/DDP 细胞对顺铂耐药可能与 Mfn2、EGFR、MMP2基因转录水平上调有关。
목적：건립인란소암순박내약세포주 OVCAR-3/DDP,초보탐토기내약궤제。방법채용순박(DDP)농도제도체증유도법,건립인란소암 OVCAR-3세포주적순박내약세포주 OVCAR-3/DDP；통과세포계수화 MTT 법평고세포증식정황,류식세포의검측세포주기정황,이평개 OVCAR-3/DDP 적생물학특성；채용 RT-PCR 법검측 Mfn2、EGFR 급 MMP2 mRNA 수평。결과성공건립료 OVCAR-3/DDP 순박내약세포주,기대 DDP 내약지수시1.92；여친본세포주 OVCAR-3상비,OVCAR-3/DDP 생장속도감만,배증기시 OVCAR-3세포적1.36배(P <0.05)；류식세포술검측결과현시세포주요정체우G2/M 기(P <0.05)；여 OVCAR-3세포상비,OVCAR-3/DDP 세포중 Mfn2、EGFR 급 MMP2 mRNA수평균명현승고(P <0.05)。결론건립적 OVCAR-3/DDP 세포주대순박내약성은정；OVCAR-3/DDP 세포대순박내약가능여 Mfn2、EGFR、MMP2기인전록수평상조유관。
Objectives To establish cisplatin-resistant human ovarian cancer cell line OVCAR-3/DDP, and discuss its resistance mechanism.Methods Stepwise selection in increasing concentration of cisplatin was adopted to establish cisplatin-resistant OVCAR-3/DDP cell line.Cell count and MTT method were used to evaluate cell proliferation;Flow cytometry was used to detect the cell cycle;RT-PCR was used to analyze the mRNA levels of Mfn2,EGFR and MMP2.Results Cisplatin-resistance cell line OVCAR-3/DDP was successfully established,DDP resistance index of which was 1.92;Cell growth of OVCAR-3/DDP cells was slow,its doubling time was 1.36-fold longer than that of OVCAR-3 cells (P <0.05);Flow cytometry results show that the cells were main stagnation in G2/M phase (P <0.05);The mRNA levels of Mfn2,EGFR and MMP2 were increased significantly in OVCAR-3/DDP compared with those in OVCAR-3 cells (P <0.05).Conclusion The cisplatin resistance of OVCAR-3/DDP cell line is stable, which probably is related to the increased expression of Mfn2,EGFR and MMP2 genes.